US › Healthcare

Kamada (KMDA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$8.67+5.86%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$54.9M

Revenue YoY

+22.7%

Net profit

$9.3M

Profit YoY

+25.6%

EPS

$0.16

EPS estimate

$0.12

Net margin

16.9%

EPS came in at 0.16 against a street estimate of 0.12 — a beat of 33.3%.

Key statistics

Market cap

$457.1M

P/E

20.8

Forward P/E

14.8

P/B

1.70

Book value

$4.66

EPS (TTM)

$0.38

Dividend yield

2.14%

52-week high

$8.89

52-week low

$6.18

50-day MA

$7.56

200-day MA

$7.85

Beta

0.14

Analyst view

Analysts rate Kamada a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $13.50.

Shareholding

Insiders

7.31%

Institutions

49.17%

Largest institutional holders

Fund	Stake
Phoenix Financial Ltd	2.87%
Two Sigma Investments LLC	0.26%
Altshuler Shaham Ltd	0.04%
Citadel Advisors Llc	0.03%
Mirae Asset Global Investments (Korea) Co Ltd	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kamada — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.